AVE's $550 Mil. Acquisition Of Bard's Cath-Lab Franchise Adds PTCA Line
This article was originally published in The Gray Sheet
Executive Summary
Arterial Vascular Engineering's $550 mil. acquisition of C.R. Bard's USCI coronary cath-lab franchise gives AVE the tools necessary to compete on a level playing field against Boston Scientific and Guidant in the estimated $3-3.5 bil. interventional cardiology market.